Authors' Reply to K. Langdon and Colleagues' Comment On: "Botulinum Toxin in the Management of Children with Cerebral Palsy"

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2019 Oct 5

PMID 31583615

Authors

Iqbal Multani

Jamil Manji

Tandy Hastings-Ison

Abhay Khot

Kerr Graham

Affiliations

Soon will be listed here.

References

Barber L, Hastings-Ison T, Baker R, Graham H, Barrett R, Lichtwark G . The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study. J Child Orthop. 2014; 7(5):425-33. PMC: 3838523. DOI: 10.1007/s11832-013-0503-x. View

Rodda J, Graham H, Carson L, Galea M, Wolfe R . Sagittal gait patterns in spastic diplegia. J Bone Joint Surg Br. 2004; 86(2):251-8. DOI: 10.1302/0301-620x.86b2.13878. View

Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N . A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013; 55(10):885-910. DOI: 10.1111/dmcn.12246. View

Multani I, Manji J, Hastings-Ison T, Khot A, Graham K . Botulinum Toxin in the Management of Children with Cerebral Palsy. Paediatr Drugs. 2019; 21(4):261-281. PMC: 6682585. DOI: 10.1007/s40272-019-00344-8. View

Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G . Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2016; 59(3):329-334. DOI: 10.1111/dmcn.13286. View

Hastings-Ison T, Sangeux M, Thomason P, Rawicki B, Fahey M, Graham H . Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study. J Child Orthop. 2018; 12(4):390-397. PMC: 6090192. DOI: 10.1302/1863-2548.12.180044. View

Paget S, Swinney C, Burton K, Bau K, OFlaherty S . Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy. Dev Med Child Neurol. 2018; 60(11):1172-1177. DOI: 10.1111/dmcn.13995. View

Graham H, Aoki K, Autti-Ramo I, Boyd R, Delgado M, Gormley M . Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000; 11(1):67-79. DOI: 10.1016/s0966-6362(99)00054-5. View

Multani I, Manji J, Tang M, Herzog W, Howard J, Graham H . Sarcopenia, Cerebral Palsy, and Botulinum Toxin Type A. JBJS Rev. 2019; 7(8):e4. DOI: 10.2106/JBJS.RVW.18.00153. View

10.

Schless S, Cenni F, Bar-On L, Hanssen B, Kalkman B, OBrien T . Medial gastrocnemius volume and echo-intensity after botulinum neurotoxin A interventions in children with spastic cerebral palsy. Dev Med Child Neurol. 2018; 61(7):783-790. DOI: 10.1111/dmcn.14056. View

11.

Hastings-Ison T, Graham K . Botulinum neurotoxin A, blinding, and bias. Dev Med Child Neurol. 2019; 62(2):259. DOI: 10.1111/dmcn.14297. View

12.

Langdon K, Copeland L, Edwards P, Rodwell K, McLennan K, Carroll T . Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy". Paediatr Drugs. 2019; 21(6):493-495. DOI: 10.1007/s40272-019-00358-2. View

13.

Valentine J, Davidson S, Bear N, Blair E, Ward R, Thornton A . Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat?. Disabil Rehabil. 2019; 43(7):936-943. DOI: 10.1080/09638288.2019.1644381. View